[ad_1]
Prestige Biopharmaceuticals The company specializing in antibody therapy development (PBP) announced that the French National Agency for the Safety of Medicines and Health Products (L’Agence nationale de sécurité du medicament, ANSM) has approved its first anti-PAUF monoclonal of its kind for the treatment of pancreatic cancer Antibody PBP1510.
The clinical trial will be conducted at the Institute of Digestive Cancer Research (IRCAD) in Strasbourg, France, for patients with pancreatic cancer who have found a pancreatic adenocarcinoma upregulation factor in most pancreatic cancers ( PAUF) gene is overexpressed. Prestige Biologics, a subsidiary of PBP, will provide drugs for clinical trials.
PBP is also preparing for this trial in other countries such as the United States, Australia, and Belgium. Korean food and…
The full story on Benzinga.com
[ad_2]
Source link
